Adults 18 to 75, any sex, with Nonalcoholic Steatohepatitis (NASH). Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Percentage of Participants Experiencing Treatment-Emergent Adverse EventsPrimary· First Dose date up to last dose (Week 12) plus 30 days
Group
Value
95% CI
Firsocostat 5 mg
70.6
Firsocostat 20 mg
71.4
Placebo
61.5
Adverse events — posted to ClinicalTrials.gov
Time frame: First Dose date up to last dose (Week 12) plus 30 days.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
NCT03987074 — Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepat
· Phase 2
· completed
NCT02891408 — Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function
· Phase 1
· completed
Other recruiting trials for Nonalcoholic Steatohepatitis (NASH)
Currently open trials in the same condition.
NCT06216041 — To Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effects of IMM-H014 in Healthy Subjects
· Phase 1
· recruiting
NCT05842512 — Study of ADI-PEG 20 Versus Placebo in Subjects With NASH
· Phase 2
· recruiting
NCT05692492 — A Randomized, Double-blind, Placebo-controlled Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NAS
· Phase 2
· active not recruiting
NCT03572465 — Quantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis
· recruiting
Other Gilead Sciences trials
Trials by the same sponsor.
NCT07115368 — Study of GS-1219 in Participants With HIV-1
· Phase 1
· terminated
NCT06784973 — Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection
· Phase 2
· terminated
NCT06683482 — A Qualitative Study on Advanced Breast Cancer Patients and Their Caregivers in Spain
· completed
NCT06613685 — Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated
· Phase 2, PHASE3
· terminated
NCT06585150 — Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection
· Phase 2
· terminated
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gilead Sciences
Last refreshed: 24 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02856555.